Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little attention has been paid as to whether in vitro studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Shabaneh, Tamer B., Downey, Sondra L., Goddard, Ayrton L., Screen, Michael, Lucas, Marcella M., Eastman, Alan, Kisselev, Alexei F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584083/
https://www.ncbi.nlm.nih.gov/pubmed/23460792
http://dx.doi.org/10.1371/journal.pone.0056132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584083/
https://www.ncbi.nlm.nih.gov/pubmed/23460792
http://dx.doi.org/10.1371/journal.pone.0056132

Ejemplares similares